The New England journal of medicine, 2022-03, Vol.386 (10), p.995-998
- Takashita, Emi
- Kinoshita, Noriko
- Yamayoshi, Seiya
- Sakai-Tagawa, Yuko
- Fujisaki, Seiichiro
- Ito, Mutsumi
- Iwatsuki-Horimoto, Kiyoko
- Chiba, Shiho
- Halfmann, Peter
- Nagai, Hiroyuki
- Saito, Makoto
- Adachi, Eisuke
- Sullivan, David
- Pekosz, Andrew
- Watanabe, Shinji
- Maeda, Kenji
- Imai, Masaki
- Yotsuyanagi, Hiroshi
- Mitsuya, Hiroaki
- Ohmagari, Norio
- Takeda, Makoto
- Hasegawa, Hideki
- Kawaoka, Yoshihiro
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Takashita, Emi
- Kinoshita, Noriko
- Yamayoshi, Seiya
- Sakai-Tagawa, Yuko
- Fujisaki, Seiichiro
- Ito, Mutsumi
- Iwatsuki-Horimoto, Kiyoko
- Chiba, Shiho
- Halfmann, Peter
- Nagai, Hiroyuki
- Saito, Makoto
- Adachi, Eisuke
- Sullivan, David
- Pekosz, Andrew
- Watanabe, Shinji
- Maeda, Kenji
- Imai, Masaki
- Yotsuyanagi, Hiroshi
- Mitsuya, Hiroaki
- Ohmagari, Norio
- Takeda, Makoto
- Hasegawa, Hideki
- Kawaoka, Yoshihiro
- Titel
- Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
- Ist Teil von
- The New England journal of medicine, 2022-03, Vol.386 (10), p.995-998
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Investigators assessed the in vitro activities of seven monoclonal antibodies and three antiviral drugs against Covid-19 variants of concern. All the antibodies showed either no or weak neutralizing activity against the omicron variant; two agents that target the RNA polymerase and a protease inhibitor were effective at omicron neutralization.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMc2119407Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8809508
- Format
- –
- Schlagworte
- Antibodies, Monoclonal - pharmacology, Antibodies, Monoclonal - therapeutic use, Antiviral activity, Antiviral agents, Antiviral Agents - pharmacology, Antiviral Agents - therapeutic use, Coronavirus, Coronaviruses, Correspondence, COVID-19, COVID-19 Drug Treatment, DNA-directed RNA polymerase, Drugs, Enzyme-Linked Immunosorbent Assay, FDA approval, Infectious Disease, Infectious diseases, Influenza, Monoclonal antibodies, Mutation, Neutralization Tests, Pathogenesis, Proteinase inhibitors, Proteins, R&D, Research & development, RNA polymerase, SARS-CoV-2 - drug effects, SARS-CoV-2 - genetics, Severe acute respiratory syndrome coronavirus 2